Efficacy of SXN in the Treatment of Iron Deficiency Anemia: A Phase IV Clinical Trial

Figure 5

The possible mechanism of SXN in promoting hematopoiesis in IDA patients. On one hand, SIC can serve as a source of supplemental quasi-heme iron; on the other hand, chlorophyll derivatives stimulate the expression of erythropoietin.